Frederik Marmé, Eva Krieghoff-Henning, Bernd Gerber, Max Schmitt, Dirk-Michael Zahm, Dirk Bauerschlag, Helmut Forstbauer, Guido Hildebrandt, Beyhan Ataseven, Tobias Brodkorb, Carsten Denkert, Angrit Stachs, David Krug, Jörg Heil, Michael Golatta, Thorsten Kühn, Valentina Nekljudova, Timo Gaiser, Rebecca Schönmehl, Christoph Brochhausen, Sibylle Loibl, Toralf Reimer, Titus J Brinker
BACKGROUND: Sentinel lymph node (SLN) status is a clinically important prognostic biomarker in breast cancer and is used to guide therapy, especially for hormone receptor-positive, HER2-negative cases. However, invasive lymph node staging is increasingly omitted before therapy, and studies such as the randomised Intergroup Sentinel Mamma (INSEMA) trial address the potential for further de-escalation of axillary surgery. Therefore, it would be helpful to accurately predict the pretherapeutic sentinel status using medical images...
October 18, 2023: European Journal of Cancer